Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

6 terminated/withdrawn out of 30 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

20%

6 trials in Phase 3/4

Results Transparency

52%

11 of 21 completed trials have results

Key Signals

2 recruiting11 with results

Enrollment Performance

Analytics

Phase 1

14(50.0%)

Phase 2

7(25.0%)

Phase 3

6(21.4%)

N/A

1(3.6%)

28Total

Phase 1(14)

Phase 2(7)

Phase 3(6)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT06569823Phase 1Recruiting

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Role: lead

NCT07207408Phase 2Recruiting

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Role: lead

NCT04177355Phase 1Completed

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Role: collaborator

NCT05506969Phase 2Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Role: lead

NCT04193189Phase 3Completed

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Role: collaborator

NCT03934736Phase 1Completed

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Role: lead

NCT03664648Unknown

DV2-HBV-27: Observational Pregnancy Registry

Role: lead

NCT04050085Phase 1Completed

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Role: collaborator

NCT05245838Phase 1Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Role: lead

NCT02521870Phase 1Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Role: lead

NCT00985426Phase 3Completed

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Role: lead

NCT04385524Not ApplicableWithdrawn

Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection

Role: collaborator

NCT02266147Phase 1Terminated

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Role: lead

NCT03326752Phase 1Completed

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Role: lead

NCT00511095Phase 2Completed

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Role: lead

NCT00403052Phase 1Terminated

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Role: lead

NCT01023230Phase 1Completed

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Role: lead

NCT00599001Phase 1Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Role: lead

NCT00387738Phase 2Terminated

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

Role: lead

NCT00537355Phase 2Completed

An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber

Role: lead